Cancer Family
Esophageal Neoplasm
CI-CAN-00000174Explore in graph →
Non-malignant555 active trials6 approved drugs12 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000174Explore in graph →
Clinical trials
2,208 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04839471 | BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)(BEAR) | completed | Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04435197 | Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma(PALACE-2) | completed | Phase 2 | 143 | Ruijin HospitalOTHER | 1 |
| Jul 3, 2024 |
| clinicaltrials |
| NCT04207918 | A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer | completed | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05807542 | Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC | completed | Phase 2 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03165994 | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | completed | Phase 2 | 34 | Apexigen America, Inc.INDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT02735239 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | completed | Phase 1 / Phase 2 | 73 | Ludwig Institute for Cancer ResearchOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT02830594 | Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 14 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03549494 | Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction | completed | Phase 2 | 45 | Catalysis SLINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03196232 | Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer | completed | Phase 2 | 3 | George Albert FisherOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL | completed | Phase 1 / Phase 2 | 133 | CytomX TherapeuticsINDUSTRY | 4 | Jan 23, 2024 | clinicaltrials |
| NCT04568200 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03600831 | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 434 | Huai'an First People's HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02916511 | Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma(ESO-Shanghai9) | completed | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT03783936 | Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | completed | Phase 2 | 18 | Ashwin SomasundaramOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT01522768 | Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer | completed | Phase 2 | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05302011 | Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02639065 | A Study of Durvalumab (MEDI4736) in Esophageal Cancer | completed | Phase 2 | 39 | Shadia Jalal, MDOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT02971956 | Pembrolizumab in Refractory Advanced Esophageal Cancer | completed | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00063986 | Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer | completed | Phase 2 | 110 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00033657 | Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer | completed | Phase 2 | 97 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT00003237 | Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach | completed | Phase 2 | 55 | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 22, 2023 | clinicaltrials |
| NCT00003864 | Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Jun 15, 2023 | clinicaltrials |
| NCT00318903 | Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer | completed | Phase 2 | 25 | University of Alabama at BirminghamOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT01333033 | PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy | completed | Phase 2 | 257 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT03888092 | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | completed | Phase 1 / Phase 2 | 81 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT02954536 | Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer | completed | Phase 2 | 37 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT01973725 | Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02976909 | Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 46 | Yuhong LiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02023593 | FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma | completed | Phase 2 | 35 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02350517 | Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer | completed | Phase 2 | 52 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02965976 | Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer | completed | Phase 2 | 33 | Roswell Park Cancer InstituteOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02976896 | Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment(Poetry-1) | completed | Phase 2 | 43 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04380480 | Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT03762564 | Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy(RAMOS) | completed | Phase 2 | 21 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT00911820 | Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | completed | Phase 2 | 88 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03660449 | Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT03416244 | A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer(RAMONA) | completed | Phase 2 | 66 | AIO-Studien-gGmbHOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT02559687 | Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) | completed | Phase 2 | 121 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 14, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT04005170 | Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer | completed | Phase 2 | 42 | Mian XIOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03925870 | KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 45 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03409848 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma(INTEGA) | completed | Phase 2 | 97 | AIO-Studien-gGmbHOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT00393068 | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer | completed | Phase 2 | 62 | SCRI Development Innovations, LLCOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT01670409 | Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer | completed | Phase 2 | 85 | Chuangzhen ChenOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT00193128 | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer | completed | Phase 1 / Phase 2 | 59 | SCRI Development Innovations, LLCOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT00591123 | Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia | completed | Phase 2 | 38 | Translational Oncology Research InternationalOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT00381706 | Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | completed | Phase 2 | 245 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | completed | Phase 2 | 101 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 20, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jul 8, 2024source: clinicaltrials